Drugs coming off patent: global patents, generics, freedom to operate formulation, manufacturers...

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BACTROBAN	mupirocin	OINTMENT;TOPICAL	050591-001	Dec 31, 1987		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Encube	MUPIROCIN	mupirocin	OINTMENT;TOPICAL	217943-001	May 13, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Fougera Pharms	MUPIROCIN	mupirocin	OINTMENT;TOPICAL	065192-001	Nov 30, 2005	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glenmark Pharms	MUPIROCIN	mupirocin	OINTMENT;TOPICAL	090480-001	Jun 8, 2011	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Padagis Us	CENTANY	mupirocin	OINTMENT;TOPICAL	050788-001	Dec 4, 2002	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Last updated: July 12, 2026

Mupirocin is a long-established topical antibiotic with mature regulatory standing and a business profile dominated by generic competition, formulation differentiation (ointment vs cream), and contract purchasing dynamics in hospitals and wound-care settings. From an IP perspective, the core value is concentrated in formulation, process, and product-specific patents rather than broad active-ingredient coverage. Investment returns are most sensitive to (1) whether a sponsor holds enforceable, product-specific patent claims, (2) whether the company can maintain premium pricing through line extensions, and (3) whether supply and regulatory strategy allow protected-market entry ahead of generic erosion.

What patents protect mupirocin (topical) and how strong is the patent estate?

Quick read: where IP value typically sits for mupirocin

For mupirocin, active-ingredient patents are long expired or near the end of term in most major markets given the drug’s historical origin and widespread generic availability. Current defensibility generally comes from:

Product-specific formulations (vehicle, concentration, excipients)
Manufacturing processes (sterility/quality, impurity control, scale-up)
Dosage form variants (ointment vs cream, optimized semisolid bases)
Label- or use-driven differentiation (less common for this molecule vs biologics)
Device or combination products where relevant (often limited for mupirocin)

Patent estate components to diligence in licensing or M&A

When assessing an investment thesis around a mupirocin franchise, diligence should focus on these claim buckets:

Formulation patents: semisolid rheology, release characteristics, penetration enhancers, preservative systems, and stability packages.
Manufacturing/process patents: impurity profiles, mixing granulation, filling controls, and validation methods that can be harder to “design around.”
Method-of-use patents: if present, these can delay label-based generics only where the generic tries to match the identical claimed use.
Continuations/divisionals: check whether assignees used continued prosecution to secure later-expiring claim sets for formulation/process.

How many patents cover mupirocin?

A complete count requires an up-to-date patent-to-product mapping (Orange Book and global patent family lists). Without jurisdictional listing data and product identifiers (strength, dosage form, NDA/ANDA numbers), the patent count cannot be stated accurately. A high-confidence approach is to:

Pull all patents listed in the US Orange Book for each mupirocin product strength/dosage form.
Build a family tree across jurisdictions based on those patent publications.
Score claim scope by remaining term, enforceability posture, and generic design-around feasibility.

When does mupirocin lose exclusivity and what drives generic erosion?

Quick read: exclusivity usually ends earlier than value does

For mature antibiotics like mupirocin, value erosion often follows:

Loss of active-ingredient or pioneer composition rights
Expiry of formulation/product patents
Loss of any remaining data exclusivity if a brand product gained protection through reformulation or new indication (rare for mupirocin)
Contract tender cycles that rapidly shift purchasing once multiple ANDA products are approved

What timing matters most for an investor

First generic approval date: indicates likely market maturity.
Patent expiry calendar: the earliest expiring product-specific patent often sets the competitive opening.
Regulatory entry lead time: formulation changes and bioequivalence package readiness can take 12 to 24 months post-ANDA planning.
Switching friction: hospitals may delay tender changes due to formulary preferences, but switches are common once supply and pricing are favorable.

Manufacturing risk as a “hidden exclusivity”

Even when legal exclusivity is gone, practical barriers can slow generic penetration:

Facility capacity and semisolid consistency
Sterility assurance for certain packaging lines
Product stability data under accelerated and long-term conditions These factors can create short windows where “effective exclusivity” is supply-driven rather than patent-driven.

Which companies are challenging mupirocin and what does Paragraph IV look like?

Quick read: most mupirocin litigation risk is generic competition, not heavy Paragraph IV

Mupirocin’s market maturity typically produces:

Multiple ANDA entrants
Pricing compression rather than frequent blockbuster-style Paragraph IV cases
Litigation concentrated around product-specific patents when formulation/process patents remain active

How to analyze Paragraph IV risk for mupirocin

The diligence framework for an investor:

Identify each mupirocin NDA product’s Orange Book-listed patents.
Map which patents have the tightest linkage to the commercial product (composition/formulation/process vs method-of-use).
Review litigation dockets to determine:
- Asserted patent claims
- Status (settled, dismissed, final judgment)
- Territory scope
- Whether settlements permit early generic launch dates
- Design-around guidance in court filings

What settlement terms typically matter

In semisolid topicals, settlements often include:

Launch date covenants
Use restrictions on certain excipients/vehicle elements
Provisions on patent challenge triggers
Dosing/strength carve-outs if multiple SKUs exist

What is the Orange Book status of mupirocin products (ointment vs cream)?

Featured snippet answer

Orange Book status must be product-specific (NDA, strength, dosage form). Mupirocin exists in multiple marketed forms and strengths, and each has its own patent listing set.

Investment implication

A company with a clean, narrow patent listing that expires late can still sustain a niche premium.
A company with few listed patents or weak claim coverage will face rapid price competition once multiple generics are approved.

How to use Orange Book data in valuation

Investors should translate patent listings into:

Remaining patent-weighted market time: sum of term remaining by patent type, weighted by relevance to generic copying.
Claim defensibility score: likelihood of invalidity/design-around success.
Regulatory risk: whether generic entrants can file with the same strength/dosage form or must change formulation.

What formulations are protected by mupirocin formulation and process patents?

Quick read: vehicle and excipient choices often drive the last mile

For topical antibiotics, formulation patents commonly protect:

Ointment base composition (hydrocarbons, polymers, stabilizers)
Cream base composition (oil-in-water systems, emulsifier selection)
Particle/solubility handling to reduce degradation and maintain potency
Preservation and antimicrobial systems for multi-dose packaging
Stability-indicating impurity profiles and acceptable ranges

What investors should look for in claim language

Whether claims are generic to the active ingredient in any vehicle (strong but uncommon)
Whether claims tie to specific excipient ratios (often weaker to design-around)
Whether process claims specify critical parameters that are difficult to replicate identically

Design-around probability for semisolid topicals

Generic developers can often change:

The base composition
The emulsifier system
Preservatives and rheology modifiers But they may struggle when patents claim:
Specific concentration windows
Stability-critical microstructure requirements
Narrow impurity profiles tied to process validation

What method-of-use patents exist for mupirocin and do they delay generics?

Quick read: method-of-use can matter if the label claim is coextensive

If method-of-use claims exist and are aligned with the approved labeling, they can:

Block “label matching” generics until patent expiry
Increase settlement leverage for the brand or licensee

Typical reality for mupirocin

For mupirocin, method-of-use protection is usually less central than formulation/process. Still, investors should search:

Any claimed use for decolonization workflows (e.g., staphylococcal decolonization) if claimed in patent estates
Any training, administration regimen, or patient population definitions

How to evaluate practical enforcement

Whether the enforcement target is “manufacturing” or “use”
Whether enforcement would require proof of patient and prescriber conduct
Whether competitors sell “non-infringing” labeling while maintaining similar clinical practice

How does mupirocin compare with other topical antibiotics for investment attractiveness?

Competitive set (clinical and commercial adjacency)

In wound care and skin infection indications, competitive pressure can come from:

Topical antiseptics/antibiotics and combinations (agents vary by country)
Systemic alternatives used off-label where topical options are constrained by payer decisions
Newer skin infection products where hospital formularies shift

What matters for mupirocin’s economics

Pricing and tender dynamics
Formulary inclusion status in major hospital systems
Availability and consistent manufacturing
Perceived resistance risk and stewardship positioning

Generic vs differentiated product strategy

Mupirocin is often a “volume product” where differentiated pricing depends on:

Supply reliability
Packaging and compliance features
Stability and shelf-life performance
Contracting relationships and rebates

What is mupirocin’s FDA regulatory status and what entry pathways apply?

Quick read: generic entry usually proceeds through ANDA

Mupirocin is a small molecule topical antibiotic, so generic entry typically uses:

ANDA pathways (bioequivalence where applicable)
Labeling that matches approved use
Chemistry, manufacturing, and controls alignment

Investor diligence for regulatory execution

Pending supplements for reformulated products
Stability updates that could affect shelf-life economics
Manufacturing site status and inspection history
Any regulatory holds tied to impurities or preservative systems

How regulatory posture impacts valuation

Even with patents, an investment thesis can fail if:

Regulatory compliance forces reformulation
Delays push launch past tender cycles
Facilities face inspection risk that blocks shipment

What generic entry risks exist for mupirocin and how can they be mitigated?

Quick read: legal risk is mostly patent-type dependent; execution risk is commercial

Generic entry risks fall into two bins:

IP freedom-to-operate risk: formulation/process claims still enforceable?
Commercial risk: even a non-infringing product faces price compression from other generics already in the market.

Mitigation strategies

Build a product-specific defensibility case: excipients, vehicle microstructure, and process-critical controls.
Structure settlements or licenses early where litigation is likely.
Use packaging and distribution advantages while patents are in force to establish share.

What patent litigation affects mupirocin and what settlement patterns matter?

Quick read: payoffs tend to be launch timing and narrow design-around covenants

For mature topicals, litigation tends to:

Set launch dates rather than permanently exclude competitors
Resolve via settlement where “carve-outs” define how generics can market
In some cases, lead to multiple reformulation cycles before a stable, non-infringing product wins acceptance

How to evaluate litigation impact for investors

Identify whether the asserted patents are composition, method, or process.
Determine whether the competitor’s product design history suggests likely non-infringement or likely settlement.
Assess whether the court’s reasoning would apply broadly across semisolid bases or narrow to specific excipient sets.

Investment scenario: commercialization drivers for mupirocin products

Commercial fundamentals investors should underwrite

Demand durability: decolonization and wound-care protocols tend to be stable; usage patterns depend on institutional stewardship and outbreak control.
Procurement mechanics: hospital purchasing often follows tender cycles, which can swing market share quickly when new generics offer favorable net pricing.
Shelf-life and supply: semisolid antibiotics can be sensitive to manufacturing consistency and stability. Supply interruptions can create temporary pricing power, but they are not sustainable if quality issues recur.
Resistance and stewardship: mupirocin resistance in certain contexts can alter clinical usage patterns, increasing competition from alternatives or antiseptics in some settings.

Where a differentiated mupirocin thesis can still work

Proprietary formulation with improved stability or reduced excipient irritation can support premium pricing in niche settings.
Co-packaged or protocol-aligned products can strengthen contracting outcomes.
A distribution-led strategy can capture share even in the presence of multiple generics if procurement relationships and service levels win.

Scenario table: investment outcomes by IP and competitive position

Scenario	IP posture	Expected competitive entry	Pricing direction	Main upside lever	Main downside lever
Brand-like defensibility	Multiple active formulation/process patents with strong claim scope	Delayed generic copies	Maintains premium	Staying ahead of tender pressure	Patent invalidation/design-around
Narrow remaining IP	Few product-specific patents near expiry	Generic erosion within 12-36 months	Moderate compression	Line extension + contracting	Faster-than-expected patent expiry
Generic-saturated market	No meaningful remaining protectable claims	Immediate full competition	Steep compression	Supply reliability and rebates	Margin collapse
Supply-led premium	Temporary manufacturing constraints for competitors	Delayed availability	Brief spike	Winning restricted supply allocation	Quality/inspection events

Key diligence checklist for an investor underwriting a mupirocin entry or license

Product mapping: each strength and dosage form (ointment vs cream) with corresponding NDA/ANDA.
Orange Book: list all patents, their types, and remaining terms; identify the “most read” patents that generic applicants are likely targeting.
Claim architecture: confirm whether claims are vehicle/excipient-specific or broadly tied to active ingredient in any base.
Manufacturing/process: evaluate whether process claims are robust and whether generic replication is plausible.
Litigation and settlements: docket history for each key patent family and any covenants that define earlier launch windows.
Commercial strategy: tender calendar, hospital formulary access, net pricing and rebate structures, and allocation strategy during supply disruptions.

Key Takeaways

Mupirocin’s investment case is driven less by active-ingredient exclusivity and more by product-specific formulation/process patents, regulatory execution, and contracting.
Generic erosion risk is high given the drug’s maturity; returns depend on enforcing remaining claims or achieving differentiation that procurement systems will fund.
The highest-value work in underwriting is Orange Book patent-to-SKU mapping and claim-scope scoring, followed by litigation/settlement pattern analysis.
Supply reliability can create short-term pricing power, but durable margins require defensibility or differentiated value.

FAQs

1) How does mupirocin resistance affect market demand and pricing power?
It can shift institutional stewardship toward alternating or limiting topical antibiotic use, increasing reliance on protocols and sometimes antiseptic substitutes, which can pressure pricing and volume.

2) Are mupirocin ointment and cream legally interchangeable for generic entry?
No, because patent listings and ANDA strategies are dosage-form specific; product switching can still be constrained by formulation and strength-specific IP and labeling.

3) What patent types usually remain for semisolid antibiotics like mupirocin?
Formulation and process patents tied to vehicle/excipient selection, stability, and manufacturing controls are the most common remaining value drivers.

4) What settlement terms most impact investor timelines in mupirocin litigation?
Launch date covenants and design-around limitations on formulation features that define whether a generic can enter with the same product profile.

5) What regulatory factors can delay or accelerate mupirocin generic launch?
CMC readiness, stability data acceptance, manufacturing site inspection outcomes, and labeling/label matching requirements can materially affect launch timing relative to patent expiry.

References (APA)

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
FDA. ANDA requirements and bioequivalence guidance for topical drug products. (Accessed 2026).

US Patents:	0
Tradenames:	3
Applicants:	10
NDAs:	16

Summary for mupirocin